-
Something wrong with this record ?
The effect of nintedanib on lung functions and survival in idiopathic pulmonary fibrosis: real-life analysis of the Czech EMPIRE registry
M. Štefániková, M. Doubková, P. Ovesná, M. Šterclová, L. Lacina, M. Žurková, M. Plačková, V. Bartoš, I. Janíčková, R. Bittenglová, J. Anton, Ľ. Sýkorová, V. Lošťáková, P. Musilová, H. Šuldová, R. Mokošová, J. Didyk, L. Šišáková, P. Lisá, J....
Language English Country England, Great Britain
Document type Journal Article
NLK
BioMedCentral
from 2001-12-01
BioMedCentral Open Access
from 2001
Directory of Open Access Journals
from 2001
Free Medical Journals
from 2001
PubMed Central
from 2001
Europe PubMed Central
from 2001
ProQuest Central
from 2009-01-01
Open Access Digital Library
from 2001-09-01
Open Access Digital Library
from 2001-01-01
Open Access Digital Library
from 2001-01-01
Medline Complete (EBSCOhost)
from 2001-01-01
Health & Medicine (ProQuest)
from 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2001
Springer Nature OA/Free Journals
from 2001-12-01
- MeSH
- Idiopathic Pulmonary Fibrosis * drug therapy MeSH
- Humans MeSH
- Lung MeSH
- Registries MeSH
- Vital Capacity MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Geographicals
- Czech Republic MeSH
INTRODUCTION: The antifibrotic drug nintedanib is used for the treatment of idiopathic pulmonary fibrosis (IPF). We analysed the effect of nintedanib on antifibrotic treatment outcome in real-world cohorts of Czech EMPIRE registry. PATIENTS/METHODS: Data of 611 Czech IPF subjects, 430 (70%) treated with nintedanib (NIN group), 181 (30%) with no-antifibrotic treatment (NAF group) were analysed. The influence of nintedanib on overall survival (OS), pulmonary function parameters as forced vital capacity (FVC) and diffusing lung capacity for carbon monoxide (DLCO), as well as GAP score (gender, age, physiology) and and CPI (composite physiological index) were investigated. RESULTS: During 2 year follow-up we observed that nintedanib treated patients had longer OS, compared to those treated with no-antifibrotic drugs (p < 0.00001). Nintedanib reduces risk of mortality over no-antifibrotic treatment by 55% (p < 0.001). We have observed no significant difference in the rate of FVC and DLCO decline between the NIN and NAF group. Changes within 24 months from baseline in CPI were not significant between the groups (NAF and NIN). CONCLUSION: Our real-practice study showed the benefit of nintedanib treatment on survival. There were no significant differences between NIN and NAF groups in changes from baseline in FVC %, DLCO % predicted and CPI.
Department of Pulmonary Medicine and Allergology Hospital Kromeriz Kromeriz Czech Republic
Department of Pulmonary Medicine and Thoracic Surgery Hospital Na Bulovce Prague Czech Republic
Department of Pulmonary Medicine Hospital Ceske Budejovice Ceske Budejovice Czech Republic
Department of Pulmonary Medicine Hospital Jihlava Jihlava Czech Republic
Department of Pulmonary Medicine Hospital Novy Jicin Novy Jicin Czech Republic
Department of Pulmonary Medicine Regional Hospital Pardubice Pardubice Czech Republic
Department of Pulmonary Medicine Tomas Bata Regional Hospital Zlin Czech Republic
Department of Pulmonary Medicine University Hospital Plzen Pilsen Czech Republic
Institute of Biostatistics and Analyses Faculty of Medicine Masaryk University Brno Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23011498
- 003
- CZ-PrNML
- 005
- 20231124105844.0
- 007
- ta
- 008
- 230718s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1186/s12890-023-02450-3 $2 doi
- 035 __
- $a (PubMed)37138274
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Štefániková, Marianna $u Department of Pulmonary diseases and tuberculosis, Faculty of Medicine, Masaryk University, University Hospital, Brno, Czech Republic. stefanikova.marianna@fnbrno.cz
- 245 14
- $a The effect of nintedanib on lung functions and survival in idiopathic pulmonary fibrosis: real-life analysis of the Czech EMPIRE registry / $c M. Štefániková, M. Doubková, P. Ovesná, M. Šterclová, L. Lacina, M. Žurková, M. Plačková, V. Bartoš, I. Janíčková, R. Bittenglová, J. Anton, Ľ. Sýkorová, V. Lošťáková, P. Musilová, H. Šuldová, R. Mokošová, J. Didyk, L. Šišáková, P. Lisá, J. Lněnička, H. Dařičková, D. Doležel, J. Pšikalová, R. Tyl, R. Králová, MK. Vašáková
- 520 9_
- $a INTRODUCTION: The antifibrotic drug nintedanib is used for the treatment of idiopathic pulmonary fibrosis (IPF). We analysed the effect of nintedanib on antifibrotic treatment outcome in real-world cohorts of Czech EMPIRE registry. PATIENTS/METHODS: Data of 611 Czech IPF subjects, 430 (70%) treated with nintedanib (NIN group), 181 (30%) with no-antifibrotic treatment (NAF group) were analysed. The influence of nintedanib on overall survival (OS), pulmonary function parameters as forced vital capacity (FVC) and diffusing lung capacity for carbon monoxide (DLCO), as well as GAP score (gender, age, physiology) and and CPI (composite physiological index) were investigated. RESULTS: During 2 year follow-up we observed that nintedanib treated patients had longer OS, compared to those treated with no-antifibrotic drugs (p < 0.00001). Nintedanib reduces risk of mortality over no-antifibrotic treatment by 55% (p < 0.001). We have observed no significant difference in the rate of FVC and DLCO decline between the NIN and NAF group. Changes within 24 months from baseline in CPI were not significant between the groups (NAF and NIN). CONCLUSION: Our real-practice study showed the benefit of nintedanib treatment on survival. There were no significant differences between NIN and NAF groups in changes from baseline in FVC %, DLCO % predicted and CPI.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a idiopatická plicní fibróza $x farmakoterapie $7 D054990
- 650 _2
- $a plíce $7 D008168
- 650 _2
- $a vitální kapacita $7 D014797
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a registrace $7 D012042
- 651 _2
- $a Česká republika $7 D018153
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Doubková, Martina $u Department of Pulmonary diseases and tuberculosis, Faculty of Medicine, Masaryk University, University Hospital, Brno, Czech Republic
- 700 1_
- $a Ovesná, Petra $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Šterclová, Martina $u Department of Respiratory Medicine, University Thomayer Hospital, Charles University, Prague, Czech Republic $u Department of Pulmonary Medicine, Faculty of Medicine at Charles University in Prague, University Hospital in Motol, Prague, Czech Republic
- 700 1_
- $a Lacina, Ladislav $u Department of Pulmonary Medicine and Thoracic Surgery, Hospital Na Bulovce, Prague, Czech Republic
- 700 1_
- $a Žurková, Monika $u Department of Pulmonary Diseases and Tuberculosis, Faculty of Medicine and Dentistry, Palacky University in Olomouc, University Hospital Olomouc, Olomouc, Czech Republic
- 700 1_
- $a Plačková, Martina $u Department of Pulmonary Diseases and Tuberculosis, Faculty of Medicine, University of Ostrava, University Hospital Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Bartoš, Vladimír $u Department of Pulmonary Medicine, Faculty of Medicine in Hradec Kralove at Charles University in Prague, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
- 700 1_
- $a Janíčková, Ivana $u Department of Pulmonary Diseases and Tuberculosis, Faculty of Medicine, University of Ostrava, University Hospital Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Bittenglová, Radka $u Department of Pulmonary Medicine, University Hospital Plzen, Pilsen, Czech Republic
- 700 1_
- $a Anton, Jan $u Department of Respiratory Medicine, University Thomayer Hospital, Charles University, Prague, Czech Republic
- 700 1_
- $a Sýkorová, Ľubica $u Department of Pulmonary diseases and tuberculosis, Faculty of Medicine, Masaryk University, University Hospital, Brno, Czech Republic
- 700 1_
- $a Lošťáková, Vladimíra $u Department of Pulmonary Diseases and Tuberculosis, Faculty of Medicine and Dentistry, Palacky University in Olomouc, University Hospital Olomouc, Olomouc, Czech Republic
- 700 1_
- $a Musilová, Pavlína $u Department of Pulmonary Medicine, Hospital Jihlava, Jihlava, Czech Republic
- 700 1_
- $a Šuldová, Hana $u Department of Pulmonary Medicine, Hospital Ceske Budejovice, Ceske Budejovice, Czech Republic
- 700 1_
- $a Mokošová, Radka $u Department of Pulmonary Diseases and Tuberculosis, Faculty of Medicine, University of Ostrava, University Hospital Ostrava, Ostrava, Czech Republic $7 xx0310631
- 700 1_
- $a Didyk, Jurij $u Department of Pulmonary Diseases and Tuberculosis, Regional Medical Association, JSC - Masaryk Hospital in Usti nad Labem, Usti nad Labem, Czech Republic
- 700 1_
- $a Šišáková, Lenka $u Department of Pulmonary Medicine, Tomas Bata Regional Hospital, Zlin, Czech Republic
- 700 1_
- $a Lisá, Pavlína $u Department of Pulmonary Medicine, Faculty of Medicine at Charles University in Prague, University Hospital in Motol, Prague, Czech Republic $7 xx0310633
- 700 1_
- $a Lněnička, Jaroslav $u Department of Pulmonary Diseases and Tuberculosis, Regional Medical Association, JSC - Masaryk Hospital in Usti nad Labem, Usti nad Labem, Czech Republic
- 700 1_
- $a Dařičková, Hana $u Department of Pulmonary Diseases and Tuberculosis, Faculty of Medicine, University of Ostrava, University Hospital Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Doležel, Daniel $u Department of Pulmonary Diseases and Tuberculosis, Regional Medical Association, JSC - Masaryk Hospital in Usti nad Labem, Usti nad Labem, Czech Republic
- 700 1_
- $a Pšikalová, Jana $u Department of Pulmonary Medicine and Allergology, Hospital Kromeriz, Kromeriz, Czech Republic
- 700 1_
- $a Tyl, Richard $u Department of Pulmonary Medicine, Hospital Novy Jicin, Novy Jicin, Czech Republic
- 700 1_
- $a Králová, Renata $u Department of Pulmonary Medicine, Regional Hospital Pardubice, Pardubice, Czech Republic
- 700 1_
- $a Vašáková, Martina Koziar $u Department of Respiratory Medicine, University Thomayer Hospital, Charles University, Prague, Czech Republic
- 773 0_
- $w MED00008206 $t BMC pulmonary medicine $x 1471-2466 $g Roč. 23, č. 1 (2023), s. 154
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37138274 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230718 $b ABA008
- 991 __
- $a 20231124105837 $b ABA008
- 999 __
- $a ok $b bmc $g 1963734 $s 1197763
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 23 $c 1 $d 154 $e 20230503 $i 1471-2466 $m BMC pulmonary medicine $n BMC Pulm Med $x MED00008206
- LZP __
- $a Pubmed-20230718
